Use search to browse all 100+ peptides
Egrifta, TH9507
A synthetic growth hormone-releasing hormone analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.
Yen. Debra W DW; Sherman. Kenneth E KE
People with HIV often develop fatty liver disease that can lead to scarring, especially if they gain belly fat from some newer HIV meds. While many drugs can affect the liver, a growth‑hormone‑releasing peptide called tesamorelin looks promising for treating this fat‑related liver damage, but solid clinical data are still limited.
Stanley. Takara L TL; Fourman. Lindsay T LT; Zheng. Isabel I; McClure. Colin M CM; Feldpausch. Megha...
The study found that lower liver production of IGF‑1 and changes in IGF‑binding proteins (IGFBPs) are linked to worse fatty liver and higher blood sugar. Giving a growth‑hormone‑releasing hormone (GHRH) altered several IGFBPs in the blood, which could affect liver fat and glucose control. This suggests that tesamorelin, a GHRH analog, might influence metabolic health in people with fatty liver, though the data are from a small HIV‑positive group.
Jain. Suyog Subhash SS; Ramteke. Karuna Balwant KB; Raparti. Girish Tulsidas GT; Kalra. Sanjay S
Long‑term HIV drugs can cause a mix of fat‑distribution problems and metabolic issues that raise heart‑attack and stroke risk. Doctors treat this by swapping to less harmful meds, using cholesterol‑lowering drugs, diabetes meds, and sometimes growth‑hormone‑like drugs such as tesamorelin, plus surgery if needed. Keeping up with these options helps spot and manage the side‑effects early.
Falutz. Julian J; Allas. Soraya S; Blot. Koenraad K; Potvin. Diane D; Kotler. Donald D; Somero. Mich...
In a 26‑week trial, daily injections of 2 mg tesamorelin cut deep belly fat by about 15% and improved cholesterol and triglyceride levels in people with HIV, without major changes in blood sugar. The drug also boosted IGF‑I, showing strong growth‑hormone activity, and side effects were similar to placebo.
Glesby. Marshall J MJ; Albu. Jeanine J; Chiu. Ya-Lin YL; Ham. Kirsis K; Engelson. Ellen E; He. Qing...
Giving growth hormone (or similar peptides like tesamorelin) can shrink belly fat in HIV patients, but it also makes the body less sensitive to insulin and raises blood sugar. Adding the diabetes drug rosiglitazone blocks these sugar problems while still keeping the fat‑loss effect.
Corley. Michael J MJ; Letendre. Scott L SL; Nightingale. Sam S
A recent HIV conference highlighted that even when the virus is well‑controlled, bits of it can stay active in the brain and spinal fluid, which may contribute to mental and cognitive problems. Researchers found connections between these issues and things like artery inflammation, genetic risk for Alzheimer’s, pollution exposure, and faster biological aging. They also reported early trial data on drugs such as tesamorelin, which is being tested to see if it can help protect the brain in people with HIV.
Hu. Miao M; Tomlinson. Brian B
Tesamorelin is a synthetic hormone that boosts your body's own growth hormone release. In two big studies with HIV patients, it cut down the dangerous belly fat that builds up around organs. However, we still don’t know how safe it is for long‑term use or whether it lowers heart disease risk, so more research is needed before it can be recommended for everyone.
Monroe. Anne A
Tesamorelin (TH9507) is a lab‑made hormone that tells your body to release more growth hormone, and early trials show it can shrink the deep belly fat that builds up in some HIV patients with lipodystrophy, also helping some blood‑fat and insulin issues. It’s still experimental for most people, but the data suggest it could become a useful tool for cutting visceral fat if you can get a prescription and manage the cost and side‑effects.
Rahman. Farah F; McLaughlin. Taryn T; Mesquita. Pedro P; Morin. Josee J; Potvin. Diane D; De Chantal...
Tesamorelin, a lab-made hormone that tells your body to release growth hormone, was shown to shrink belly fat (visceral fat) and waist size in people with HIV, whether or not they had a fatty hump on the back of their neck. The effect was the same in both groups.
Dhillon. Sohita S
Tesamorelin is a lab-made hormone that boosts your body’s own growth hormone. In people with HIV who have extra belly fat, it cuts down the deep, dangerous fat around the organs (visceral fat) without much change to the skin‑deep fat. The effect lasts while you keep taking it, but the fat comes back if you stop. Side effects are generally mild, like sore injection spots, joint aches, headaches, or slight swelling.
Rochira. Vincenzo V; Guaraldi. Giovanni G
In people with HIV, especially those on antiretroviral therapy, growth hormone production is often blunted, leading to excess belly fat (visceral fat). Giving tesamorelin, a drug that mimics the natural hormone that tells the pituitary to release growth hormone, has been shown to shrink that dangerous fat without the side‑effects seen with high‑dose synthetic growth hormone.
Teng. Shirley S; Potvin. Diane D; Mamputu. Jean-Claude JC; Vincent. Geneviève G; Zoltowska. Mon...
Tesamorelin doesn't meaningfully change how the liver enzyme CYP3A processes common drugs like simvastatin (a cholesterol pill) and ritonavir (an antiviral). In healthy volunteers, the drug levels stayed within the normal range, so you don't need to adjust the doses of these meds when you take tesamorelin.
Falutz. Julian J; Allas. Soraya S; Mamputu. Jean-Claude JC; Potvin. Diane D; Kotler. Donald D; Somer...
In HIV patients with excess belly fat, daily injections of tesamorelin for a year safely cut deep abdominal fat (visceral fat) by about 18% and lowered triglycerides dramatically, without causing major blood‑sugar problems. The benefits disappear once the drug is stopped.
Chege. Boniface M BM; Mwangi. Peter W PW; Githinji. Charles G CG; Bukachi. Frederick F
In rats, a high‑calorie, low‑protein diet combined with HIV drugs caused weight gain, high blood sugar, bad cholesterol, and liver fat. Adding tesamorelin, a synthetic hormone that boosts growth hormone release, largely prevented these metabolic problems.
Adrian. S S; Scherzinger. A A; Sanyal. A A; Lake. J E JE; Falutz. J J; Dubé. M P MP; Stanley. T...
In people with HIV who lost a lot of belly fat after taking tesamorelin, the drug also made the muscles in the torso denser (less fat inside) and a bit bigger. The effect was seen after about six months of treatment.
Wang. Ying Y; Tomlinson. Brian B
Tesamorelin is a synthetic hormone that tells your body to release more growth hormone. In a large trial it helped people with HIV shrink the dangerous belly fat around their organs and was generally safe, but it didn’t show strong benefits for other health problems.
Fourman. Lindsay T LT; Czerwonka. Natalia N; Feldpausch. Meghan N MN; Weiss. Julian J; Mamputu. Jean...
In HIV patients with excess belly fat, the drug tesamorelin shrank visceral fat by at least 8% and this was linked to lower liver enzymes (ALT and AST), which are markers of liver health. The benefit stuck around even after stopping the drug, though some fat came back.
González-Sales. Mario M; Barrière. Olivier O; Tremblay. Pierre Olivier PO; Nekka. Fahima F...
The study shows that daily low‑dose tesamorelin (1‑2 mg) reliably raises growth hormone and IGF‑1 levels in both HIV‑positive patients and healthy people, and this effect doesn’t seem to depend on age, weight, sex, or race. The researchers built a model that can predict how these hormones will change over time with the drug.
Mangili. Alexandra A; Falutz. Julian J; Mamputu. Jean-Claude JC; Stepanians. Miganush M; Hayward. Br...
Tesamorelin, a synthetic hormone that boosts growth hormone release, was shown to cut deep belly fat (visceral fat) in HIV patients with excess abdominal fat. After six months, people on tesamorelin were almost four times more likely to get their visceral fat below a health‑risk threshold (140 cm²) compared to placebo. The biggest responders tended to have metabolic syndrome (by NCEP criteria), high triglycerides, or be white.
Gattu. Arijeet K AK; Fourman. Lindsay T LT
People living with HIV often develop a liver condition called MASLD, which can get worse faster than in people without HIV. The disease is driven by both the usual causes of fatty liver and HIV‑specific issues like changes in body shape, chronic inflammation, leaky gut, and some HIV medicines. Early studies suggest that the growth‑hormone‑releasing peptide tesamorelin may help improve liver health in this group, but more research is needed.